Table 2.
Viability screening on pancreatic cancer cell lines following 48 hr treatment.
| |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Activity, EC50 (μM)a
|
|||||||||
| Cmpd | R | R1 | Panc02 | KP02 | KCKO | MIAPaCa-2 | BxPC3 | AsPC1 | Panc-1 |
| 1 | A | CH3 | 1.33±0.2 | 6.92±0.9 | 6.49±1.0 | 14.6±2.2 | 2.34±0.8 | 2.01±0.6 | 14.6±2.1 |
| 2 | B | CH3 | 1.17±0.4 | 7.32±0.8 | 6.18±0.3 | 10.8±1.3 | 6.15±0.6 | 3.86±0.2 | 8.73±0.8 |
| 7 | H | CH3 | 1.21 ±0.1 | 2.83±0.6 | 3.14±0.4 | 18.3±2.1 | 2.52±0.5 | 2.17±0.3 | >100 |
| 8 | H | H | >100 | >100 | >100 | >100 | >100 | >100 | n.d.b |
| 9 | C | CH3 | 2.18±0.3 | 5.62±1.1 | 4.51±0.8 | 10.3±1.9 | 5.93±0.7 | 5.74±0.5 | n.d.b |
| |||||||||
| Activity, EC50 (μM)a
|
|||||||||
| Cmpd | X | BM | Panc02 | KP02 | KCKO | MIAPaCa-2 | BxPC3 | AsPC1 | Panc-1 |
| 10 | H | A | >100 | >100 | >100 | >100 | >100 | >100 | n.d.b |
| 11 | H | B | >100 | >100 | >100 | >100 | >100 | >100 | n.d.b |
| 13 | C | A | >100 | 49±2.5 | 77±5.2 | 40±3.5 | >100 | >100 | n.d.b |
| 14 | C | B | >100 | 70±4.6 | 67±4.5 | 79±6.1 | >100 | >100 | n.d.b |
a
Values represent the mean of n ≥ 3 separate experiments in duplicate ± SEM
b
n.d. = not determined.